go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd
Stonemason's Way, Rathfarnham, Dublin 16,
Telephone: +353 1 495 5000
Fax: +353 1 495 5105
Medical Information Direct Line: +353 1 800 244 255
Medical Information Facsimile: +353 1 495 5242
Summary of Product Characteristics last updated on medicines.ie: 28/10/2010
SPC Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28/10/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 5.4 - Radiation dosimetry
Date of revision of text on the SPC:   30-Sep-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Changes to Section 4 & 5
Updated on 22/02/2010 and displayed until 28/10/2010
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
Date of revision of text on the SPC:   01-Jan-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



SUMMARY OF SPC CHANGES (MARKED IN RED)

 

 

1.       Trade Name of the Medicinal Product

 

          Augmentin Paediatric 125mg/31.25mg per 5ml Paediatric Powder for Oral Suspension

 

 

2.       Qualitative and Quantitative Composition

 

            Each 5 ml of reconstituted suspension contains Amoxicillin Trihydrate Ph.Eur. equivalent to 125 mg of amoxicillin and potassium clavulanate equivalent to 31.25 mg of clavulanic acid.

           

            Excipient:  Each 5ml of reconstituted oral suspension contains 12.5mg of Aspartame (E951).

 

For a full list of excipients, see section 6.1

 

 

6.       Pharmaceutical Particulars

 

6.1     List of Excipients

           

            Xanthan gum (E415)

Hypromellose (E464)

Aspartame (E951)

Silicon dioxide Colloidal hydrated Silica

Silica colloidal anhydrous silica

Succinic acid

Raspberry dry flavour

Orange dry flavour 1

Orange dry flavour 2

Golden syrup dry flavour

 

6.3     Shelf-life

 

            Dry powder: 24 months 2 Years

            Reconstituted suspension according to directions: 7 days

            Discard any unused suspension seven days after reconstitution.

 

6.4     Special Precautions for Storage

 

            Dry powder should be stored in the original container: Do not store above 25°C. Store in the original container to protect from moisture.

            Reconstituted suspensions should be according to directions: Stored at between 2°C and 8°C. (but not frozen) for up to seven days. Do not freeze.

 

6.6     Instructions for Use/Handling Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

 

            At time of dispensing the dry powder should be reconstituted to form an oral suspension.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Updated on 04/07/2008 and displayed until 22/02/2010
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   06/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

OLD SPC Wording

 

 

            Renal impairment

            In patients with moderate or severe renal impairment dosages should be adjusted according to the degree of impairment.

 

Creatinine clearance

Dosage ml/min

Interval mg

hr

10 - 30

15/3.75* mg/kg

 

12 (b.i.d.)

< 10

15/3.75* mg/kg

 

24 (o.d.)

           

            * using the Paediatric Suspension

 

 

NEW SPC Wording

 

            Renal impairment

            In patients with moderate or severe renal impairment dosages should be adjusted according to the degree of impairment.

 

Creatinine clearance

Dosage ml/min

Interval mg

hr

10 - 30

15/3.75* mg/kg

(maximum 500/125mg twice daily)

12 (b.i.d.)

< 10

15/3.75* mg/kg

(maximum 500/125mg)

24 (o.d.)

           

            * using the Paediatric Suspension

Updated on 20/12/2006 and displayed until 04/07/2008
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   09/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

4.5...............

Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of amoxicillin-clavulanate and allopurinol.

In common with other antibiotics, amoxicillin-clavulanate may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives....................

4.8...................

Gastrointestinal disorders

Very common Diarrhoea

Common Nausea, vomiting

Nausea is more often associated with higher oral dosages. If gastrointestinal reactions are evident, they may be reduced by taking AUGMENTIN at the start of a meal.

Uncommon Indigestion

Very Rare Antibiotic-associated colitis (including pseudomembranous colitis and haemorrhagic colitis).

Black hairy tongue

............................

Updated on 18/01/2006 and displayed until 20/12/2006
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
Updated on 12/05/2004 and displayed until 18/01/2006
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
Updated on 19/06/2003 and displayed until 12/05/2004
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Amoxicillin trihydrate
   Potassium clavulanate

Versions

 
28/10/2010 to Current
22/02/2010 to 28/10/2010
04/07/2008 to 22/02/2010
20/12/2006 to 04/07/2008
18/01/2006 to 20/12/2006
12/05/2004 to 18/01/2006
19/06/2003 to 12/05/2004
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo